Storm victims' families get Rs 4 lakh aid in Ghaziabad, Noida payout today
Mujammil (40), who was driving back home after finishing work in Sahibabad, was crushed under a tree that got uprooted during the squall in Madhuban Bapudham.
Bhanu Devi (38) died after the boundary wall of a private school in Khoda Colony collapsed onto her shanty.
Five members of her family were also injured in the incident.
After meeting the families, the minister said officials have been directed to ensure dependents are given benefits as per public welfare schemes. "UP has assured of govt support beyond immediate compensation," he said.
In addition to the Rs 4 lakh ex-gratia, the administration has submitted an application for a widow pension of Rs 1,000 per month for Mujammil's wife, Amir Jahan, and Rs 5,000 per month under the Bal Seva Yojana—Rs 2,500 each for the couple's two children.
Applications were also submitted under the Kanya Sumangala Yojana for educational support and for a one-time grant of Rs 30,000 under the Family Benefit Scheme.
Bhanu Devi's husband, Ravindra Bind, said their two children were enrolled for monthly assistance of Rs 5,000 under the Bal Seva Yojana. The minister visited a local clinic in Khoda to check on two injured individuals who were also injured in the adjacent house—Santosh and Ganesh—and directed the health department to ensure they face no hurdles in treatment.
A third woman, Shameem (35), had died in Ghaziabad after she slipped into a drain and sustained head injuries while returning home during the storm. Police officials had told TOI that the woman's leg got stuck in a drain, causing her to fall. District administration officials said it was not identified as a death caused by the storm.
Meanwhile, the minister in-charge of GB Nagar, Brijesh Singh, will hand over the compensation to the families of the three persons killed in Noida on Sunday.
Fifty-year-old Sunita and her two-year-old grandson Advik had died when a large tin sheet, torn loose by strong winds from the roof of their 21-storey tower in Greater Noida's Migsun Ultimo, fell on them as they rushed toward the building's lobby from the play area. In another incident, Ramakrishna, a 45-year-old laboratory technician at DAV Inter College, died when a tree fell on him during an evening walk in NTPC township.
He was found pinned under the tree by workers clearing debris after the storm and was rushed to NTPC Hospital, where he was declared dead on arrival.
"Rs 4 lakh each will be given to the families of the three deceased in Noida. Minister in-charge Brijesh Singh will personally hand over the compensation award on Sunday," said ADM Atul Kumar.
At least 49 people died across Uttar Pradesh due to various rain and storm-related incidents between 8 pm on May 21 to 4 pm on May 22, according to a report of the Integrated Disaster Control Centre, Relief Commissioner's Office, Lucknow.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
2 hours ago
- New Indian Express
Remote centres outside Kerala force candidates to drop out of NEET-PG
THIRUVANANTHAPURAM/KOCHI: With just two days remaining for the National Eligibility Entrance Test-Postgraduate (NEET-PG), on August 3, many medical graduates are shocked to get examination centres outside the state — in Andhra Pradesh, Tamil Nadu and Karnataka. Many candidates had carefully chosen cities near their residences as preferred centres during the application process. However, many were stunned to be assigned locations hundreds of kilometres away. 'I'm not appearing for the exam this time. I've been allotted a centre in Telangana, and I'm eight months pregnant. The travel and stay costs are too high for me and my family,' said Dr Kavitha (name changed), a candidate from Thiruvananthapuram. 'Other young mothers in my batch are opting out too. We've paid Rs 4,000 for the application, and now we're forced to abandon the attempt.' Surveys conducted by several junior doctor associations revealed that approximately 1,000 applicants from Kerala were given centres outside the state. The uncertainty over exact venue details — only disclosed two days prior to the exam on July 31 — adds to the logistical nightmare. 'If I had received Kollam as my centre, I could reach anywhere nearby without issues. But with a location like Visakhapatnam, I don't even know how close the centre will be to a hotel. How do we plan ahead?' said Dr Ashik Basheer, state president of the General Practitioners Association. Candidates have also voiced concerns over inflated travel and accommodation prices.
News18
3 hours ago
- News18
Weight Loss Drug Mounjaro May Help Diabetics Live Longer, Protect The Heart & Kidneys: Eli Lilly
Last Updated: The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said In a major development that could shift the way obesity is treated globally, Eli Lilly's weight loss and type 2 diabetes drug tirzepatide, sold as the brands Mounjaro and Zepbound, has been shown to significantly reduce the risk of serious cardiovascular complications, including heart failure and chronic kidney disease. Eli Lilly on Thursday announced results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies—Mounjaro and Trulicity—in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Trulicity—made by Lilly—is not insulin, but it helps the body release insulin more effectively after meals. About tirzepatide Tirzepatide works by mimicking two gut hormones—GIP and GLP-1—that regulate appetite, insulin response, and energy use. This dual-action mechanism sets it apart from earlier drugs and is believed to drive both its weight loss and cardiometabolic benefits. In the SURPASS-CVOT study, Mounjaro (tirzepatide) was shown to be as safe as Trulicity in preventing serious heart issues like heart attack, stroke, or heart-related death. While not the focus of the study, Mounjaro also showed better results in lowering blood sugar (A1C), reducing weight, improving kidney function, and lowering overall death risk. The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company claimed. These results hold significance for India, as the American pharma giant launched the drug here on March 20, and since then, the drug has seen rapid uptake. In just three months, sales soared to Rs 12.6 crore in May, tripling from March, according to Pharmatrac data. Priced at Rs 4,375 (5 mg) and Rs 3,500 (2.5 mg) per vial, Mounjaro's monthly cost ranges from Rs 14,000-17,500, nearly 80% cheaper than US prices. While the results from the trial are promising, detailed results for SURPASS-CVOT will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 in September and published in a peer-reviewed journal. Lilly said it plans to submit the data to global regulatory authorities by the end of this year. 'Cardiovascular disease remains the leading cause of death among people living with type 2 diabetes," Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, wrote in the press release issued by the drugmaker. 'The SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 receptor agonist, while providing additional benefits, including greater kidney protection and a reduced overall risk of death. These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease." Findings of the study In the trial, the risk of cardiovascular death, heart attack, or stroke was 8% lower for Mounjaro vs Trulicity, meeting the prespecified criteria for non-inferiority. In simple words, Mounjaro reduced the risk of heart-related problems (heart attack, stroke, or heart death) by 8% compared to Trulicity. It also lowered the overall risk of death by 16%. A separate analysis using past trial data suggested Mounjaro may reduce heart risks by 28% and death risk by 39% compared to a theoretical placebo. In people with serious kidney problems, Mounjaro slowed kidney decline more effectively than Trulicity over three years. In the trial, Mounjaro helped patients improve their blood sugar (A1C), lose more weight, and showed better heart-related health markers like cholesterol and blood pressure compared to Trulicity. Both medicines had similar safety profiles. The most common side effects were stomach-related issues like nausea or diarrhoea, which were mostly mild and got better over time. However, 13.3% of people on Mounjaro stopped treatment due to side effects, compared to 10.2% on Trulicity. Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hans India
3 hours ago
- Hans India
Human milk bank offering lifeline to fragile newborns
Tirupati: A silent revolution has been unfolding at the Government Maternity Hospital in Tirupati, one drop at a time. The Rotary Human Milk Bank, launched just over a year ago on April 3, 2024, has emerged as a vital support system for fragile newborns unable to receive their mother's milk, while simultaneously fostering greater public awareness about milk donation. This initiative holds particular significance as the theme for this year's World Breastfeeding Week (August 1 to 7) is 'Prioritise Breastfeeding: Create Sustainable Support Systems'. Established with a generous Rs 30 lakh contribution from the Rotary Club of Tirupati, the bank's mission is clear: to ensure every infant receives safe, life-sustaining nourishment during their most vulnerable phase, irrespective of their mother's health. With approximately 1,200 deliveries annually at the hospital, the need for such a facility was evident. Many babies are born prematurely or face complications that hinder breastfeeding, often leading to reliance on formula or unprocessed milk, both of which carry potential health risks. "Breast milk is a divine gift for a newborn. It strengthens the baby's body and boosts immunity," explained Dr B Manohar, Head of Paediatrics at SV Medical College. "However, some mothers - such as those who have undergone premature delivery or had complications during childbirth - may not be able to produce sufficient milk. For such babies, the Human Milk Bank is a great help." The milk bank bridges this gap by collecting surplus milk from healthy, lactating mothers. This donated milk undergoes rigorous safety protocols: potential donors are screened for infections like HIV, Hepatitis B (HBsAg), and Hepatitis C (HCV), often during their admission for delivery. "Mothers who are healthy and lactating in abundance can donate their excess milk. This milk is thoroughly tested, pasteurised, stored hygienically, and given to needy newborns. When you donate your milk, you may be saving a newborn's life," Dr Manohar added. K Bhuvaneswari, Manager of the milk bank, noted the efforts to sensitize mothers post-delivery on the importance of donation. While many mothers are willing, we still face resistance from their elders, especially in-laws, who discourage them, she said. Despite these challenges, awareness is clearly on the rise. From April to December 2024, 643 mothers donated milk, and an additional 459 mothers contributed from January 2025 to date. One mother even garnered appreciation from the district collector for donating over 2,000 ml. The Human Milk Bank provides approximately 30 ml of breast milk daily to each infant in need, particularly those admitted to the neonatal ICU. Its benefits have also extended to supporting children recovering from surgeries at the Padmavathi Children's Heart Centre. This facility has undeniably become a crucial component of neonatal care within the hospital, immensely benefiting numerous infants. Beyond the recipients, mothers who donate also experience advantages. Experts suggest that breast milk donation helps regulate supply, prevents engorgement, and contributes to overall maternal well-being.
